{"prompt": "['Novartis', 'Confidential', 'Page 82', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Criteria', 'Actions required', 'Follow-up monitoring', 'Establish causality', 'Complete liver CRF', '> 3 to 5 x ULN', 'Repeat LFT within the next week', 'ALT, AST, TBL, Alb, PT/INR, ALP and', '(patient is', 'If elevation is confirmed, initiate close', 'yGT until resolution (frequency at', 'asymptomatic)', 'observation of the patient', 'investigator discretion)', 'ALP (isolated)', '> 2 x ULN (in the', 'Repeat LFT within 48 hours', 'Investigator discretion', 'absence of known', 'If elevation persists, establish causality', 'Monitor LFT within 1 to 4 weeks or at', 'bone pathology)', 'Complete liver CRF', 'next visit', 'TBL (isolated)', '> 2 x ULN (in the', 'Repeat LFT within 48 hours', 'ALT, AST, TBL, Alb, PT/INR, ALP and', 'absence of known', 'If elevation persists, discontinue the study', 'yGT until resolution (frequency at', 'Gilbert syndrome)', 'drug immediately', 'investigator discretion)', 'Hospitalize if clinically appropriate', 'Test for hemolysis (e.g., reticulocytes,', 'Establish causality', 'haptoglobin, unconjugated [indirect]', 'bilirubin)', 'Complete liver CRF', '> 1.5 to 2 x ULN', 'Repeat LFT within the next week', 'Investigator discretion', '(patient is', 'If elevation is confirmed, initiate close', 'Monitor LFT within 1 to 4 weeks or at', 'asymptomatic)', 'observation of the patient', 'next visit', 'Jaundice', 'Discontinue the study treatment immediately', 'ALT, AST, TBL, Alb, PT/INR, ALP and', 'Hospitalize the patient', 'yGT until resolution\u00b0 (frequency at', 'Establish causality', 'investigator discretion)', 'Complete liver CRF', 'Any AE potentially', 'Consider study treatment interruption or', 'Investigator discretion', 'indicative of a liver', 'discontinuation', 'toxicity*', 'Hospitalization if clinically appropriate', 'Establish causality', 'Complete liver CRF', 'Elevated ALT/AST > 3 x ULN and TBL > 2 x ULN but without notable increase in ALP to > 2 x ULN', '(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia', 'Resolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable values at', 'three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after a maximum of 6', 'months, (4) liver transplantation, and (5) death.', 'Abbreviations: ULN (upper limit of normal), ALT (alanine aminotransferase), AST (aspartate aminotransferase),', 'TBL (total bilirubin), ALP (alkaline phosphatase), INR (international normalized ratio), PT, Alb (albumin), LFT (lung', 'function test), CRF (case report form).']['Novartis', 'Confidential', 'Page 83', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', '15', 'Appendix 3: Specific Renal Alert Criteria and Actions', 'Table 15-1', 'Specific Renal Alert Criteria and Actions', 'Serum Event', 'Serum creatinine increase', 'Confirm 25% increase after 24-48h', '25 - 49% compared to baseline', 'Follow up within 2-5 days', 'Acute Kidney Injury: Serum creatinine increase', 'Follow up within 24-48h if possible', '50% compared to baseline', 'Consider study treatment interruption', 'Consider patient hospitalization /specialized treatment', 'Urine Event', 'Albumin-creatinine ratio (ACR) >1g/g or >100', 'Confirm value after 24-48h', 'mg/mmol;', 'Perform urine microscopy', 'Protein-creatinine ratio (PCR 1) 1g/g or >100', 'Consider study treatment interruption / or discontinuation', 'mg/mmol', 'For all renal events:', 'Document contributing factors in the CRF: co-medication, other co-morbid conditions, and additional diagnostic', 'procedures performed', \"Monitor patient regularly (frequency at investigator's discretion) until either:\", 'Event resolution: sCr within 10% of baseline or protein-creatinine ratio within 50% of baseline, or', 'Event stabilization: sCr level with 10% variability over last 6 months or protein-creatinine ratio stabilization at', 'a', 'new level with 50% variability over last 6 months.']\n\n###\n\n", "completion": "END"}